Latest news with #arrhythmia
Yahoo
23-07-2025
- Health
- Yahoo
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
Health Line
16-07-2025
- Health
- Health Line
Types of Atrial Fibrillation: What You Need to Know
Key takeaways AFib is classified into four types based on how long the irregular heartbeat lasts: paroxysmal, persistent, long-standing persistent, and permanent. Paroxysmal AFib comes and goes on its own, while persistent AFib lasts longer and may require medical intervention. Long-standing persistent AFib lasts for at least a year, and permanent AFib is continuous. Treatment options vary depending on the type of AFib, but the goals are to restore normal heart rhythm, manage heart rate, and prevent blood clots. Overview Atrial fibrillation (AFib) is a type of arrhythmia, or irregular heartbeat. It causes the upper and lower chambers of your heart to beat out of sync, fast, and erratically. AFib used to be classified as either chronic or acute. But in 2014, new guidelines from the American College of Cardiology and American Heart Association changed the classification of atrial fibrillation from two types to four: paroxysmal AFib persistent AFib long-standing persistent AFib permanent AFib You can start with one type of AFib that eventually becomes another type as the condition progresses. Keep reading to learn more about each type. 1. Paroxysmal atrial fibrillation Paroxysmal AFib comes and goes. It begins and ends spontaneously. The irregular heartbeat may last anywhere from several seconds to a week. However, most episodes of paroxysmal AFib resolve themselves within 24 hours. Paroxysmal AFib may be asymptomatic, which means that you experience no apparent symptoms. The first line of treatment for asymptomatic paroxysmal AFib may be lifestyle changes, such as reducing daily caffeine consumption and reducing stress, in addition to medications as preventative measures. 2. Persistent atrial fibrillation Persistent AFib also begins spontaneously. It lasts at least seven days and may or may not end on its own. Medical intervention such as cardioversion, in which your doctor shocks your heart into rhythm, may be needed to stop an acute, persistent AFib episode. Lifestyle changes and medications may be used as preventive measures. 3. Long-standing persistent atrial fibrillation Long-standing persistent AFib lasts at least a year without interruption. It's often associated with structural heart damage. This type of AFib can be the most challenging to treat. Medications to maintain a normal heart rate or rhythm are often ineffective. More invasive treatments may be needed. These can include: electrical cardioversion catheter ablation pacemaker implantation 4. Permanent atrial fibrillation Long-standing persistent AFib can become permanent when treatment doesn't restore normal heart rate or rhythm. As a result, you and your doctor make a decision to stop further treatment efforts. This means your heart is in a state of AFib all the time. According to research, this type of AFib may result in more severe symptoms, lower quality of life, and an increased risk of a major cardiac event.
Globe and Mail
08-07-2025
- Health
- Globe and Mail
Emerald Coast Heart & AFib Brings Specialized Cardiac Rhythm Care to Fort Walton Beach Under the Leadership of Dr. Ian Weisberg
Crestview, Florida--(Newsfile Corp. - July 8, 2025) - Board-certified cardiac electrophysiologist Dr. Ian Weisberg has announced the expansion of Emerald Coast Heart & AFib, a groundbreaking medical practice focused exclusively on diagnosing and treating heart rhythm disorders. Originally established in Crestview, Florida, the center is now extending its reach to Fort Walton Beach, offering more patients in Northwest Florida access to highly specialized arrhythmia care. Dr. Ian Weisberg To view an enhanced version of this graphic, please visit: Dr. Ian Weisberg, a distinguished physician with over ten years of experience in cardiac electrophysiology, has earned national recognition for his contributions to arrhythmia management and procedural excellence. A graduate of the University of Chicago's renowned medical program, he performs more than 300 atrial fibrillation ablations annually and is known for his innovative leadership in developing state-of-the-art heart rhythm programs across the region. "Far too often, arrhythmias like atrial fibrillation are misinterpreted or overlooked, which can lead to increased risk of stroke, heart failure and worsened quality of life" said Dr. Ian Weisberg. "At Emerald Coast Heart & AFib, we're focused on delivering prompt, expert, and compassionate care that is tailored to each individual's needs-right here in their own community." The Crestview clinic has rapidly earned a reputation for clinical excellence and compassionate, personalized care. Now, with its expansion into Fort Walton Beach, the practice aims to serve a broader population spanning from Milton to Navarre. The new location will continue offering a full suite of advanced treatments for cardiac rhythm disorders, ensuring convenient access to specialized care that was previously limited in the area. Key services provided by Emerald Coast Heart & AFib include: Personalized treatment plans for atrial fibrillation Catheter ablation and electrical cardioversion Pacemaker and defibrillator (ICD) implantation Left atrial appendage occlusion using the Watchman™ device Remote cardiac monitoring and loop recorder implantation Stroke prevention strategies and heart-healthy lifestyle education Each patient at the practice benefits from a deeply individualized approach, blending high-tech care with a strong emphasis on education and empowerment. Dr. Ian Weisberg and his team prioritize patient understanding, ensuring that individuals are fully informed about their diagnoses and the available treatment paths. As part of his commitment to community outreach and patient education, Dr. Weisberg also founded a digital resource offering clear, evidence-based information about atrial fibrillation and related heart rhythm disorders. The platform serves as an extension of the clinic's philosophy: to educate and support patients beyond the walls of the medical office. "Our vision is to make world-class electrophysiology services accessible right here on the Emerald Coast," said Dr. Ian Weisberg. "Patients shouldn't have to leave their community to receive the level of care that these conditions demand. We're here to fill that gap with expertise, empathy, and innovation." Clinic Locations: Crestview Office 550 W Redstone Ave, Suite 430 Crestview, FL 32536 Milton Office 5992 Berryhill Rd, Suite 301 Milton, FL 32570 Fort Walton Beach Office (Opening Soon) For more information or to schedule an appointment, visit: To view the source version of this press release, please visit
Health Line
08-07-2025
- Health
- Health Line
A Guide to Drugs for Arrhythmia
Key takeaways Medications for arrhythmia include antiarrhythmic drugs that restore the heart's normal rhythm by affecting the heart's electrical current. Calcium channel blockers can help manage arrhythmia, angina, and high blood pressure by widening blood vessels and slowing the heart rate. Anticoagulants are prescribed to reduce the risk of blood clots and stroke in people with arrhythmia, but they require monitoring for internal bleeding. Introduction An arrhythmia is a condition in which the heart beats too quickly, too slowly, or irregularly. In many cases, the arrhythmia may not be serious or require any treatment at all. However, if your doctor finds that the arrhythmia could lead to more serious heart problems, they may prescribe medication. Several types of medication can help control or resolve an arrhythmia. The type that's right for you depends on the kind of arrhythmia you have. Here's what to know about drugs that treat arrhythmia. Antiarrhythmic drugs Antiarrhythmic drugs may be prescribed if you have tachycardia (fast heart rate) or premature or extra heartbeats. These medications work to correct the rhythm of your heart. They restore a normal heart rhythm by changing the electrical current that makes your heart beat. Most antiarrhythmic drugs come in pill form and are typically used long-term. In emergencies, some can be given intravenously. The most common medications in this class are: amiodarone (Cordarone, Pacerone) flecainide (Tambocor) ibutilide (Corvert), which can only be given through IV lidocaine (Xylocaine), which can only be given through IV procainamide (Procan, Procanbid) propafenone (Rythmol) quinidine (many brand names) tocainide (Tonocarid) While these medications can help correct an arrhythmia, there's also a risk that they can cause the arrhythmia to occur again or more often. This is called a proarrhythmia. If you develop a proarrhythmia while taking an antiarrhythmic drug, call your doctor right away. Calcium channel blockers If you have angina (chest pain), high or low blood pressure, and an arrhythmia, your doctor may prescribe a calcium channel blocker. These drugs dilate your blood vessels. This allows more blood to flow to the heart, which helps ease chest pain and decrease blood pressure. These drugs can also slow your heart rate. A reduced heart rate and lowered blood pressure reduce the strain on your heart and reduce your risk of an arrhythmia. Most calcium channel blockers come in pill form, but some are also available in intravenous (IV) form. Calcium channel blockers are for long-term use. Examples of common calcium channel blockers include: amlodipine (Norvasc) diltiazem (Cardizem, Tiazac) felodipine isradipine nicardipine (Cardene SR) nifedipine (Procardia) nisoldipine (Sular) verapamil (Calan, Verelan, Covera-HS) The side effects of these medications vary. Some people have tachycardia, dizziness, constipation, and headaches. Other people more serious side effects include rash or swelling in the legs and feet. Beta blockers If you've been diagnosed with tachycardia, your doctor may prescribe a beta-blocker. Beta-blockers stop the action of the hormone adrenaline. This can relieve your tachycardia by slowing your heart rate. It can also lower your blood pressure and decrease the stress on your heart. Examples of beta blockers include: acebutolol (Sectral) atenolol (Tenormin) bisoprolol (Zebeta) metoprolol (Lopressor, Toprol-XL) nadolol (Corgard) propranolol (Inderal LA, InnoPran XL) The side effects of beta-blockers include tiredness, cold hands, and headache. Sometimes these medications affect your digestive system as well. Some people report stomach issues, constipation, or diarrhea. Anticoagulants An anticoagulant is a blood-thinning medication. Your doctor may prescribe an anticoagulant if your arrhythmia puts you at risk of clots or stroke caused by a clot. For some people, an abnormal heart rhythm changes how the blood flows through their system. For instance, atrial fibrillation may cause blood to pool in the heart, which may result in blood clots. Anticoagulants don't fix your heart rhythm problem. They only help reduce the risk of blood clots caused by certain arrhythmias. Warfarin (Coumadin) is one of the most common anticoagulants. However, non-vitamin K oral anticoagulants (NOACs) are now recommended over warfarin unless you have moderate to severe mitral stenosis or an artificial heart valve. NOACs include: dabigatran (Pradaxa) rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) Anticoagulants are effective, but they can also make your body less able to stop bleeding. For this reason, you should watch for any signs of internal bleeding, such as bloody stool, multiple bruises, and vomit that looks like coffee grounds. Your doctor may prescribe aspirin instead of warfarin if they find that you have a lower risk of a blood clot. Aspirin is not as powerful of a blood thinner as warfarin is. However, it has a lower risk of causing bleeding.
Associated Press
20-06-2025
- Business
- Associated Press
IBN Coverage: HeartBeam (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam's plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational clearance also sets the stage for future advancements, including 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. HeartBeam's long-term vision is to revolutionize cardiac care by enabling continuous, predictive insights outside traditional clinical settings. To view the full press release, visit About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to BEAT are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]
